Mifepristone (Korlym) for Cushing's Syndrome
The FDA has approved the antiprogestin mifepristone
(Korlym – Corcept Therapeutics) for control of hyperglycemia
secondary to hypercortisolism in adults with
endogenous Cushing’s syndrome who have type 2 diabetes/
glucose intolerance and have not responded to,
or are not candidates for, surgery. Formerly known as
RU 486, mifepristone is also available in a lower
strength as Mifeprex for use in terminating an early
intrauterine pregnancy....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Mifepristone (Korlym) for Cushing's Syndrome
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1392
Article Code: 1392c
Date: June 11, 2012
Volume: 54
Pages: 46-47
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1392
Article Code: 1392c
Date: June 11, 2012
Volume: 54
Pages: 46-47
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
